Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
F-FDG PET/CT in lymphangiosarcoma: A case report and review of literature.
Asia Ocean J Nucl Med Biol
January 2025
Department of Nuclear medicine, Dr Rajendra Prasad government medical college, India.
Objectives: Lymphangiosarcoma is a rare tumor that affects the upper limbs of patients who have undergone breast cancer surgery, including axillary dissection, followed by radiation therapy (RT) to the axilla and has a poor prognosis. F-FDG PET/CT may enable the earlier detection of malignant transformation in a setting of chronic lymphedema and help evaluate the extent and staging of the tumor, allowing earlier initiation of treatment options.
Case Presentation: We herein report a case of cutaneous lymphangiosarcoma in a 47-year-old breast carcinoma patient, which occurred 9 years after initial surgery and radiation therapy.
Off-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Lower Extremity Angiosarcoma: A Life-Threatening Complication of Lymphedema.
Adv Skin Wound Care
May 2024
At Mayo Clinic, Rochester, Minnesota, USA, Vishal Garimella, MBBS, and Nimay Anand, BA, are Visiting Research Fellows; Elliott H. Campbell, MD, is Dermatology Resident Physician; and Christian L. Baum, MD, and Afsaneh Alavi, MD, are Professors of Dermatology. Acknowledgments: Afsaneh Alavi is on the Board of Directors for the Hidradenitis Suppurativa Foundation and served as a consultant for AbbVie, Almirall, Boehringer Ingelheim, InflaRx, Incyte, Kymera, Novartis, and UCB and investigator for Boehringer Ingelheim, and Processa. The authors have disclosed no other financial relationships related to this article. Submitted January 10, 2023; accepted in revised form June 16, 2023.
Article Synopsis
- * The symptoms of angiosarcoma can vary widely, presenting as anything from bleeding spots to larger masses, which may eventually lead to serious complications like ulceration.
- * Treatment requires a comprehensive approach involving surgery, radiation, and chemotherapy, and there is currently limited research on lower limb cases, prompting the need for healthcare providers to consider angiosarcoma in patients with lymphedema-related symptoms.
Patient with composite haemangioendothelioma containing angiosarcoma-like areas in the setting of congenital lymphoedema mimicking Stewart-Treves syndrome: a case report.
Diagn Pathol
June 2023
Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Article Synopsis
- Composite haemangioendothelioma is a rare vascular tumor that can exhibit low to medium malignant potential and is diagnosed by identifying different vascular components through histopathology.
- A case study describes a 49-year-old man with chronic lymphoedema who developed this tumor, which showed high-grade angiosarcoma-like features but behaved less aggressively, confusing it with the more severe Stewart-Treves syndrome.
- Despite needing potentially extensive surgery (hemipelvectomy), the patient opted against it and, after two years of monitoring, experienced no disease progression, indicating the need for accurate diagnosis to avoid unnecessary procedures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!